Kornimate/medical-research-clean huggingface dataset:
phenotypic and genetic correlates of diabetes (non-type 1) in young non-obese asian indians in north india and a study to evaluate the efficacy of sitagliptin (dpp-4 inhibitor) in a sub-group of the study population

Conditions: Diabetes Mellitus, Type 2

Summary: this is a phase iv study of 3.5 years duration to evaluate the phenotypic and genetic correlates of diabetes (non-type 1 in young non-obese asian indians in north india and pilot case control study to evaluate the efficacy of sitagliptin (dpp-4 inhibitor) in a sub-group of the study population.

a phase iv on t2dm with bmi \< 25 kg/m2 and age 14-40 years. primary objectives: * to investigate phenotype (body composition, anthropometry, pancreatic imaging and endocrine function, insulin resistance, autoantibodies, and other biochemical variables) and genetic (known mutations and polymorphisms) correlates in young (age 14-40 years) diabetic patients (non-type 1). secondary objectives: * to study anthropometric and body fat distribution including truncal fat, subcutaneous and intra-abdominal fat in non-obese young patients with diabetes (non-type 1). * to study whether insulin secretion, insulin resistance or a combination of both is/are the predominant defect(s) in non-obese young diabetics (non-type 1). * to study the prevalence of autoimmunity and/or specific genetic abnormalities in this subgroup of diabetics. * to estimate approximate prevalence of diagnostic subcategories based on the sample of population, and profile of complications in each category. * to propose rational use of specialized investigations (e.g. gad65, hnf-1α mutations etc) while investigating a newly diagnosed young diabetic. * to determine the rational therapeutic option and prognosis in this sub-population of diabetics based on anthropometric, biochemical, and etiological profiles. * sample size: 205 patients to be enrolled and 120 patients to be enrolled for sub group study

Eligibility criteria:
inclusion criteria: * young (18 to 40 years) patients with diabetes (not on insulin therapy) during the past 6 months and having bmi \<25 kg/m2. * drug naïve patients * patients on mono-therapy with metformin (\< 1g/day). exclusion criteria: * type 1 diabetes * type 2 diabetes on any other oral hypoglycemic agent other than metformin * pregnancy or lactation * insulin or sulfonylurea treatment within the past 3 months * has received any investigational drug with the past 60 days * history of prior allergy or hypersensitivity to any drug (unless approved by investigator) * hba1c \ 8.5%. * unstable glycemic control, requiring addition of 2nd oral agent/insulin or frequent up-titration of dose of metformin. * any patient on insulin. * females of child bearing potential who are not using adequate contraception during the study period. * insulin dependent or history of ketoacidosis requiring hospitalization * acute infections * advanced end-organ damage (cld, crf etc.) * diabetes with clinically significant or advanced end-organ damage

Keywords: maturity onset diabetes of the young 3 protein, human
df(oat bran) intervention on inflammation, intestinal flora, disease activity and quality of life in patients with ra

Conditions: Rheumatoid Arthritis

Summary: the goal of this clinical trial is to test in rheumatoid arthritis. the main question it aims to answer are: * to verify the effect of dietary fiber supplementation on reducing the level of inflammation; * to verify the effect of dietary fiber supplementation on improving disease activity and quality of life in patients with rheumatoid arthritis .to verify the effect of dietary fiber supplementation on regulating the production of anti-inflammatory short-chain fatty acid in the gut of patients with rheumatoid arthritis. the experimental group was supplemented with dietary fiber for 12 weeks, and the control group was fed with the mediterranean diet. before and after the intervention, 1 tube of 3ml blood and 1 soybean-sized stool were taken and a questionnaire was made

rheumatic arthritis (ra) is caused by chronic inflammation and joint injury caused by imbalance of pro-and anti-inflammatory mediators in the joints. studies have shown that dietary fiber (df) can be fermented by gut bacteria into anti-inflammatory short-chain fatty acid that may reduce joint inflammation, relieve symptoms and improve quality of life. the subjects were randomized controlled trial to supplement df12w individually, the intervention group to supplement df12w, and the control group to supplement df12w with routine diet, the differences of disease activity (das28 score) , inflammatory markers (tnf-a, il-6, mir-146a, treg, esr, crp, etc.) and quality of life (sf-36) between the two groups were compared. the changes of intestinal flora were examined to verify the hypothesis. this study laid a good scientific foundation for dietary recommendation of ra patients.

Eligibility criteria:
inclusion criteria: * patients diagnosed with rheumatoid arthritis according to the 2010 acr/eular classification criteria, with a course of ≥ 2 years, and no changes in anti rheumatic drugs within 8 weeks prior to intervention; * age: 18-75 years old; * das28-esr ≥ 2.6 points, and fully controlled and treated with medication during screening visits; * sign an informed consent form and be able to complete the experiment according to the protocol. exclusion criteria: * patients with mental illness, cognitive impairment, severe heart, lung, brain failure, serious complications, pregnancy, or life-threatening diseases; * patients with severe visual or auditory impairment and inability to understand research information; * during the past 8 weeks of treatment with disease modifying anti rheumatic drugs (dmards), patients with food intolerance, allergies, and unwillingness to consume the intervention food in the study; * in the past 10 years, there has been a history of tumors and eating disorders (such as neurogluttony, anorexia, binge eating, etc.); * participated in other intervention studies in the past three months.

Keywords: rheumatoid arthritis dietary fiber mechanism
the effectiveness of the adapted bridge's self-management programme

Conditions: Self-Care; Self Efficacy

Summary: the effectiveness of the adapted bridge's self-management programme in south african community-dwelling stroke survivors: a randomized controlled trial with two arms will be used, with the intervention group receiving self-management sessions delivered by experienced therapists and usual care and control group will only receive usual care which includes a information booklet.

this study aim to determine the effectiveness of the adapted bridges self-management intervention on south african stroke patients' functional activity, self-efficacy, and participation. method: this experimental study will make use of a randomized controlled design (rct), consisting of one hundred and sixty eight stroke survivors recruited from different health care facilities within the cape metropolitan area. the study participants will be divided randomly into two groups, with one receiving the intervention - the experimental group - and the other receiving an educational booklet - the control group. participants will be assessed at baseline, immediately post-intervention (six weeks), three and sixth-month post intervention, using standardized outcome measures (both subjective outcome measures and objective clinical tools). ethical clearance and permission to conduct the study will be obtained and patient information will be kept confidential. analyses will be conducted using descriptive statistics of frequencies and percentages for categorical variables and mean and standard deviation for continuous variables. given the assumptions of equal variance, a two-way full factorial anova will be computed in order to assess interaction between groups and intervention type.

Eligibility criteria:
inclusion criteria: * having a first ever stroke, by a physician, based on the who (1988) definition of stroke which is "rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than of vascular origin"; ≥18 years of age; of sufficient cognition to participate: having a score of ≥24 points on mini-mental state examination (placing participants at matched mental status) ; are medically stable and; and are within the sub-acute to chronic phase of their rehabilitation (10 weeks to 6-months post stroke). exclusion criteria: * participants will be excluded if they have serious medical conditions such as hiv/aids or tb, which could additionally affect the outcomes evaluated in this study. participants with depression, having recurrent stroke, still receiving in inpatient rehabilitation, with cognitive or receptive language difficulties and are unable to comprehend the intervention will be excluded.

Keywords: stroke, self-management, bridges, participation, function, self-efficacy
postoperative residual paralysis after cardiac surgery

Conditions: Postoperative Residual Curarization

Summary: the main objective of this study is to describe the incidence of postoperative residual paralysis (mean train-of-four \<90%) when weaning from the ventilator in patients admitted to the intensive care unit (icu) after elective cardiac surgery. train-of-four monitoring is a widely used term for the peripheral nerve stimulation used in neuromuscular blockade monitoring. when the patient is ready for weaning from the ventilator, an icu doctor will perform a measurement of the train-of-four at the thumb with a neuromuscular transmission monitor. every value below 90% will be considered as residual paralysis and treated appropriately by means of a reversal agent.

postoperatively, in the icu, readiness-for-weaning is based on icu doctor-nurse-driven institutional weaning guidelines: 6 hours after arrival in the icu, a patient who is normothermic, hemodynamically stable, has normal blood gasses and absence of residual bleeding. the icu nurse caring for the patient will start weaning the patient from the ventilator, following these departmental guidelines.

Eligibility criteria:
inclusion criteria: * patients admitted to the icu after elective cardiac surgery exclusion criteria: * emergency cardiac surgery

Keywords: neuromuscular blockade neuromuscular monitoring
effects of movement pattern training versus proprioceptive neuromuscular training in footballers with groin pain

Conditions: Sports Physical Therapy

Summary: effects of movement pattern training versus proprioceptive neuromuscular facilitation on pain range of motion flexibility and kick distance among footballers with groin pain.

according to the literature, due to the small number of pt studies on elite athletes (compared with the number of studies on general athletes), it is necessary to further understand whether pt can also benefit this group and accurately test the sports science equipment to facilitate the planning of accurate training courses.there is limited number of studies that have investigated comparative effects of pattern training and propiocetive neuro muscular facilitation..also, there was no study found that effects of movement pattern training versus proprioceptive neuromuscular facilitation on pain range of motion flexibility and kick distance among footballers with groin pain.

Eligibility criteria:
inclusion criteria: * history of groin or adductor strain patient neurological involvement that influenced coordination or balance * male players,groin pain during or after the game * groin pain \> 8 weeks. * tenderness on palpation. * pain during hip adduction with resistance * willingness to participate in the research exclusion criteria: * subjects with urinary tract infection * lower limb fractures, * metastasis * spinal pathology, * hip joint osteoarthritis * inguinal pain(2).

Keywords: groin hip movements physiotherapy rehabilitation
immunophenotyping from blood of patients with malignant gliomas

Conditions: Anaplastic Astrocytoma; Glioblastoma Multiforme

Summary: in this explorative study immunological changes during tumor therapy will be analyzed in patients with malignant glioma. immunophenotyping before and during therapy is used as analysis method. thereby immune cells are quantitatively and qualitatively detected from patient's blood at continuous time points. additionally relevant mediators like cytokines, danger signals and chemokines are analyzed by other methods. obtained results may give information about the effects of therapy on immunological processes and immune cells and may help to find immunological based predictive or prognostic tumor markers and to define time points for including additional immune therapy in the future.

patients with malignant glioma generally have a bad prognosis. to improve patients' situation new therapy options as well as new possibilities to determine prognosis and prediction more precisely are needed. one approach is the targeted activation of the immune system to recognize and eliminate tumor cells. due to cerebral tumors the brain is no immune privileged organ anymore, so that immune cells may pass the haemato-encephalic barrier to attack tumor cells. this study aims to offer valuable clues about how the immune system is influenced by standard therapies (radiotherapy and chemotherapy). just with the background knowledge of immune mechanisms and influencing factors by tumor therapy, an effective anti-tumor response can systematically be induced by modulating immune therapy. to analyze immunological changes, immunophenotyping by flow cytometry is performed with blood from patients with malignant gliomas during their therapy concluding chemoradiation and chemotherapy alone. count, class and activation status of immune cells are detected by flow cytometry. together with additional analysis methods, information about immunological mediators like cytokines, chemokines and danger signals can be received. for these purposes serum and plasma are generated from blood samples and stored for prospective questions. the explorative determined results may also help to discover new, immunological based, prognostic or predictive tumor markers.

Eligibility criteria:
inclusion criteria: * patients with glioblastoma or anaplastic astrocytoma * legal age * planned chemoradiation and adjuvant chemotherapy (according to stupp et. al.) exclusion criteria: * fertile patients who refuse effective contraception during study treatment * persistent drug and/or alcohol abuse * patients not able or willing to behave according to study protocol * patients in care * patients that are not able to speak german

Keywords: malignant glioma anaplastic astrocytoma glioblastoma multiforme immune immunophenotyping immune cells activation state quality of live translational research
platelet concentrate in achilles tendon repair

Conditions: Achilles Tendon Rupture; Soft Tissue Injury; Tendon Injury

Summary: people operated for a rupture of the achilles tendon receive a concentrate of their own platelets injected into the operated area. the study is randomized and single-blinded, with 20 treated patients and 20 controls, who get no injection. the primary endpoint is a mechanical property of the tendon after 12 weeks (modulus of elasticity), as measured by a special type of radiography. this radiography uses 0.8 mm metal markers, which are injected into the tendon. the tendon is mechanically loaded during radiography and its strain can be measured as increased distance between the markers. other mechanical variables at 6, 12 and 52 weeks are secondary variables, as well as a validated patient-administrated questionaire at 1 year.


Eligibility criteria:
inclusion criteria: * achilles tendon rupture, age 18-65. exclusion criteria: * any counterindication for surgical treatment.

Keywords: platelets tendon ligament
multicenter registry for patients with childhood.onset craniopharyngioma, xanthogranuloma, cysts of rathke's pouch, meningioma, pituitary adenoma, arachnoid cysts

Conditions: Craniopharyngioma; Obesity

Summary: kraniopharyngeom registry 2019 will prospectively collect and descriptively analyse data on diagnostics, treatment, and follow-up of patients with craniopharyngioma. in continuation of preceding studies also patients with xanthogranuloma, meningioma, pituitary adenoma, prolactinoma and cystic intracranial malformations will be registered.


Eligibility criteria:
inclusion criteria: 1. diagnosed with craniopharyngioma for the first time 2. age at diagnosis 18 years or less of age 3. agreement from patient's parents or legal guardian as well as the patient exclusion criteria: 1. age at diagnosis over 18 years of age 2. diagnosis different from craniopharyngioma

Keywords: quality of life endocrinology oncology hypothalamus irradiation neurosurgery pediatric brain tumors
intrauterine device insertion and felt pain

Conditions: Intrauterine Device Migration

Summary: the aim of this study is to compare the pain score between the direct method and the conventional method in patients who have undergone copper or hormonal intrauterine devices (iud) for contraception and to find an answer to the question of which method is better.

the intrauterine device (iud) is one of the commonly used methods of contraception due to its effectiveness in providing reliable contraception, its ease of application, non-obstruction of sexual life, affordability, minimal absolute contraindications, and reversibility. despite this increasing preference, concerns regarding the use of both levonorgestrel-releasing and copper iuds due to the potential pain and fear of pain during insertion, which has hindered the adoption of this method. although the conventional method is used for intrauterine device insertion, the authors defined the direct method, also known as the torpedo technique, in 2006. iud practitioners have started to prefer this direct method because it is simpler, faster and has fewer insertion steps than the conventional technique. however, iud practitioners should apply the most painless and tolerable method to women who choose an iud for contraception. therefore, in order to understand which method is less painful, patients will be divided into 2 groups as those who have iud inserted with the conventional method and those who have iud inserted with the direct method. at the end of the procedure, participants in both groups will be asked to rate the most severe pain they experienced during the procedure according to the visual analogue scale (vas) (from 0 to 10). in the conventional method: the anterior lip of the cervix was grasped and pulled with pozzi forceps, and after entering the uterine cavity with a hysterometry the iud was inserted. in the direct method: the anterior lip of the cervix was grasped and pulled with pozzi forceps, and without using hysterometry the iud was directly inserted.

Eligibility criteria:
inclusion criteria: * volunteer to participate in the study * preferring an intrauterine device for the contraceptive method exclusion criteria: * patients with uterine leiomyoma * patients with endometriosis * patients with chronic pelvic pain * patients with familial mediterranean fever * patients who experienced complications during the procedure * patients who developed vasovagal reactions * patients who had previously used an iud for any reason * patients with uterine anomalies

Keywords: pain intrauterine devices conventional technique direct technique iud
anti-inflammatory activities of grapes in humans at risk for cardiovascular disease

Conditions: Obesity; Inflammation

Summary: the goal of the study is to determine whether grape consumption can reduce the risk of cardiovascular disease by reducing the presence of inflammatory molecules and positively altering cholesterol levels, lipid profiles, and immune cell responses.

obese individuals are at high risk for the development of hypertension and cardiovascular disease. adipose tissue is a major source of pro-inflammatory molecules which can promote the development of atherosclerosis. development of atherosclerotic plaques are mediated by oxidized or otherwise modified ldl cholesterol and infiltration of activated immune cells into the atherosclerotic lesions. grapes contain high levels of polyphenols, a class of compounds known to possess antioxidant and anti-inflammatory properties. the overall goal of this proposal is to determine whether grape consumption can reduce the risk of cardiovascular disease by reducing the presence of inflammatory molecules and positively altering cholesterol levels, lipid profiles, and immune cell responses. using a randomized cross-over design, twenty obese subjects will consume beverages containing either four servings of grape powder per day or the caloric equivalent without grape powder (placebo control) for a total of three weeks. after a two week washout period, the beverages will be switched for a further three weeks. blood will be taken from each person at six intervals to determine lipid profiles, measure inflammatory markers in plasma, and analyze immune cell responsiveness.

Eligibility criteria:
inclusion criteria: * bmi 30 - 45 kg/m2 * commitment to the dietary intervention and scheduled testing exclusion criteria: * subjects will be excluded from this study if their blood cell counts or blood chemistry profiles are outside of the normal range * smoking or use of tobacco products * drink more than one alcoholic beverage per day (1 oz. distilled liquor, 3 oz. wine, or 12 oz. beer) * taking cholesterol-lowering medications * taking steroids for asthma or other inflammatory states * taking thyroid-regulating drugs * taking over-the counter weight loss products
biomarker signature and musculoskeletal ultrasound profile in rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine the kinetics of change in quantitative measures of joint inflammation by state of the art power doppler vascular imaging and to identify biomarkers in biological samples (synovial biopsies, dna, rna, pbmc, serum, plasma, urine and stool samples) from parallel cohorts of ra patients undergoing different treatments. this will be achieved implementing msus assessments, standard laboratories techniques (such as elisas, gene profiling, transcriptome analysis etc.) and the novel cytof™ technology.


Eligibility criteria:
inclusion criteria: * written confirmed diagnosis of rheumatoid arthritis as per acr/eular 2010 criteria. * if patient is on oral corticosteroids, dose must be stable for 6 weeks prior to baseline visit. * willingness and ability to comply with all the study procedures. exclusion criteria: * any systemic inflammation conditions (other than ra), connective tissue disease or chronic pain disorders that may interfere with the interpretation of the outcome data. examples include psoriatic arthritis, reactive arthritis, gout, systemic lupus erythematosus (sle), polymyalgia rheumatic and/or temporal arteritis, lyme's disease, fibromyalgia and chronic fatigue syndromes. * major surgery planned within 8 weeks prior to screening or planned surgery throughout the study period. * treatment with any investigational agent ≤ 4 weeks prior to baseline (or 5 ≤ half-lives of the investigational drug, whichever is the longer). * intramuscular/intra-articular glucocorticoids for 6 weeks prior to baseline visit. * active infection. * septic arthritis within a native joint within the last 12 months. * sepsis of a prosthetic joint within 12 months or indefinitely if the joint remains in situ. * known hiv or hepatitis b/c infection. * latent tb infection unless they have completed adequate antibiotic prophylaxis. * malignancy (other than basal cell carcinoma) within the last 10 years. * new york heart association (nyha) grade 3 or 4 congestive cardiac failure. * demyelinating disease. * presence of a transplanted organ (with the exception of a corneal transplant \> 3 months prior to screening). * known recent substance abuse (drug or alcohol).